Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK and Safety of Glumetinib in Healthy Chinese Males
NCT05507294Phase 1Completed
- Sponsor
- Haihe
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glumetinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Haihe. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 5 more. Started Mar 2021; status: completed.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05507294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507294.